Quinoline triazole compound and application thereof
By designing quinoline triazole compounds, the problems of narrow therapeutic window and drug resistance of existing anti-influenza drugs have been solved, achieving effective inhibition of influenza A and B viruses and providing a safer and more effective treatment option.
Patent Information
- Application Number
- CN202411514212.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-28
- Publication Date
- 2026-04-28
AI Technical Summary
Existing anti-influenza drugs such as oseltamivir have a narrow therapeutic window and are prone to developing drug-resistant strains, while mabaloxavir has side effects and a high incidence of drug-resistant strains. There is a need to develop more effective anti-influenza virus drugs.
Provides quinoline triazole compounds and their pharmaceutically acceptable salts, stereoisomers, prodrug molecules, and deuterated derivatives for the preparation of pharmaceutical compositions for the treatment and/or prevention of respiratory viral infections, achieving antiviral activity against influenza A and influenza B viruses through rational structural design.
Quinoline triazole compounds have shown good anti-influenza activity, especially effective inhibition of influenza A and B viruses, and have broad application prospects.